ABT · 10-Q · 2026Q2 · Full report
Revenue Performance and Mix
ABBOTT LABORATORIES · 2026-07-28 · Importance 58 · Surprise 40 · No source text
Second-quarter 2026 net sales increased 13.0% to $12.593 billion, or 12.2% excluding foreign exchange, with U.S. sales rising 22.0% to $5.216 billion and international sales rising 7.5% to $7.377 billion. Six-month net sales increased 10.5% to $23.757 billion, or 8.2% excluding foreign exchange, driven by Diagnostic Products, Medical Devices, and Established Pharmaceutical Products and partially offset by a 4.5% decline in Nutritional Products. Six-month Diagnostic Products sales rose 24.7% to $5.272 billion, including approximately $1.0 billion from Exact Sciences’ Cancer Diagnostics business, while Medical Devices sales increased 11.0% to $11.392 billion. Diabetes Care sales increased 12.1% to $4.268 billion, including $4.1 billion of continuous glucose monitoring sales, while Rapid and Molecular Diagnostics declined 7.4% to $1.567 billion because of lower respiratory-virus-test demand.
Key facts
- Diagnostic Products sales were $3,092 million for the three months ended June 30, 2026, versus $2,173 million in the prior year, an increase of 42.3% (1.0% FX impact, 41.3% excl. FX).
- For the three months ended June 30, 2026, total net sales were $12,593 million, up 13.0% versus $11,142 million in the prior year (0.8% favorable FX impact, 12.2% excl. FX).
- For the six months ended June 30, 2026, total net sales were $23,757 million, up 10.5% versus $21,500 million in the prior year (2.3% favorable FX impact, 8.2% excl. FX).
- Three months ended June 30, 2026 net sales: $12,593 million.
- Six months ended June 30, 2026 net sales: $23,757 million.
- The 12.2 percent increase in total net sales during Q2 2026 excluding foreign exchange was driven by the acquisition of Exact Sciences and high single-digit growth in Medical Devices and Established Pharmaceutical Products, partially offset by lower sales in Nutritional Products.
- Three months ended June 30, 2025 net sales: $11,142 million.
- Six months ended June 30, 2025 net sales: $21,500 million.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +9.5% | For the six months ended June 30, 2026, total net sales were $23,757 million, up 10.5% versus $21,500 million in the prior year (2.3%… |
| revenue | positive | realized | +3.9% | Diagnostic Products sales were $3,092 million for the three months ended June 30, 2026, versus $2,173 million in the prior year, an… |
| revenue | positive | realized | — | Three months ended June 30, 2026 net sales: $12,593 million. |
| revenue | positive | realized | — | Six months ended June 30, 2026 net sales: $23,757 million. |